Syncona Limited — Regulatory Filings 2021

Jul 30, 2021

National Storage Mechanism | Additional information

RNS Number : 1001H

Syncona Limited

30 July 2021

Syncona Limited

Total Voting Rights

30 July 2021

Pursuant to DTR 5.6.1 Syncona Limited (the "Company") announces that as at 30 July 2021 the total number of ordinary shares in issue now stands at 666,733,588 and the total number of voting rights in the Company is 666,733,588.

The Company does not hold any ordinary shares in treasury.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

[ENDS]

Enquiries

Syncona Ltd

Annabel Clay/Fergus Witt

Tel: +44 (0) 20 3981 7940

FTI Consulting

Brett Pollard / Natalie Garland-Collins/Tim Stamper

Tel: +44 (0) 20 3727 1000

Copies of this press release and other corporate information can be found on the company website at: www.synconaltd.com  

About Syncona:

Syncona's purpose is to invest to extend and enhance human life. We do this by founding, building and funding a portfolio of global leaders in life science, to deliver transformational treatments to patients in areas of high unmet need.

Our strategy is to found, build and fund companies around exceptional science to create a dynamic portfolio of 15-20 globally leading healthcare businesses for the benefit of all our stakeholders. We focus on developing treatments for patients by working in close partnership with world-class academic founders and management teams. Our balance sheet underpins our strategy enabling us to take a long-term view as we look to improve the lives of patients with no or few treatment options, build sustainable life science companies and deliver strong risk-adjusted returns to shareholders.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRFLFLLDRIIVIL